Wolverine Trading LLC lowered its stake in Kindred Biosciences Inc (NASDAQ:KIN) by 21.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,422 shares of the biopharmaceutical company’s stock after selling 6,656 shares during the quarter. Wolverine Trading LLC owned about 0.09% of Kindred Biosciences worth $231,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Nationwide Fund Advisors purchased a new stake in Kindred Biosciences in the 2nd quarter worth $100,000. SG Americas Securities LLC purchased a new stake in shares of Kindred Biosciences during the 3rd quarter valued at about $123,000. The Manufacturers Life Insurance Company raised its position in shares of Kindred Biosciences by 18,470.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,756 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 18,655 shares in the last quarter. Trexquant Investment LP raised its position in shares of Kindred Biosciences by 88.6% during the 3rd quarter. Trexquant Investment LP now owns 26,228 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 12,325 shares in the last quarter. Finally, California State Teachers Retirement System purchased a new stake in shares of Kindred Biosciences during the 2nd quarter valued at about $321,000. Institutional investors and hedge funds own 64.36% of the company’s stock.
Shares of NASDAQ:KIN opened at $8.45 on Friday. The stock has a market cap of $235.38, a P/E ratio of -6.87 and a beta of 0.08. Kindred Biosciences Inc has a 12 month low of $6.50 and a 12 month high of $9.80.
Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.02). equities analysts predict that Kindred Biosciences Inc will post -1.5 earnings per share for the current fiscal year.
KIN has been the topic of several recent research reports. Aegis restated a “buy” rating on shares of Kindred Biosciences in a research report on Friday, December 15th. HC Wainwright set a $11.00 target price on shares of Kindred Biosciences and gave the company a “buy” rating in a research report on Friday, March 2nd. ValuEngine upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, January 13th. Finally, BMO Capital Markets restated a “hold” rating on shares of Kindred Biosciences in a research report on Friday, December 22nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $9.79.
In other Kindred Biosciences news, Director Raymond Townsend sold 2,670 shares of the company’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $9.45, for a total value of $25,231.50. Following the transaction, the director now directly owns 25,057 shares in the company, valued at approximately $236,788.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Richard Chin sold 20,000 shares of the company’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $8.39, for a total transaction of $167,800.00. Following the completion of the transaction, the insider now owns 2,266,071 shares in the company, valued at $19,012,335.69. The disclosure for this sale can be found here. Insiders have sold a total of 22,761 shares of company stock worth $193,891 over the last quarter. 19.10% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Kindred Biosciences Inc (KIN) Shares Sold by Wolverine Trading LLC” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/wolverine-trading-llc-has-231000-holdings-in-kindred-biosciences-inc-kin.html.
Kindred Biosciences Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.